Nurse Practitioner Program year 2025 Reported 2023–2025 Source: CMS Open Payments, 2026 publication

Crystal Kimball

Nurse Practitioner, Primary Care Ukiah, CA Nurse Practitioner

NPI 1316646797 CMS profile 11487764

880 Sanel Dr, Ukiah, CA 95482

Open in the dashboard

General payments

$291

8 records reported · program years 2023–2025

Research payments

$0

Paid to them · None reported · program years 2023–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Crystal Kimball of Ukiah, CA is reported in the CMS Open Payments database as having received $291 across 8 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 47th percentile of Nurse Practitioner, Primary Care profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

3 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $152 4
2024 General $24 1
2023 General $115 3

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Crystal Kimball
  • Nurse Practitioner, Primary Care median
  • Middle half of Nurse Practitioner, Primary Care
  • National median

In program year 2025, general payments to Crystal Kimball were reported at $152. Among 4,814 Nurse Practitioner, Primary Care profiles paid that year, the median was $169 and the middle half received between $51 and $499.

Show as a table
Year Crystal Kimball Nurse Practitioner, Primary Care median Middle half National median
2019 $0 — — $163
2020 $0 — — $114
2021 $0 $137 $39–$445 $132
2022 $0 $139 $44–$421 $149
2023 $115 $163 $53–$481 $160
2024 $24 $176 $54–$511 $164
2025 $152 $169 $51–$499 $169

Breakdown

Who paid General payments · program years 2023–2025
  1. Novo Nordisk Inc $125 1 payment
  2. AbbVie, Inc. $93 2 payments
  3. Mayne Pharma Inc. $37 3 payments
  4. Boehringer Ingelheim Pharmaceuticals, Inc. $22 1 payment
  5. GlaxoSmithKline, LLC. $14 1 payment

Every payment, record by record

What the payments were for General payments · program years 2023–2025
  1. Food and Beverage $291 8 payments
Products named General payments · program years 2023–2025
  1. Ozempic $125 1 payment
  2. DALVANCE $70 1 payment
  3. RINVOQ $23 1 payment
  4. JARDIANCE $22 1 payment
  5. SHINGRIX $14 1 payment
  6. BEXSERO $14 1 payment

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 67 drugs

Part D claims

2,529

Median for Nurse Practitioner: 389

Drug cost

$146,920

Median for Nurse Practitioner: $21,885

Branded share of claims

19%

Median for Nurse Practitioner: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Jardiance Empagliflozin Brand 39 $37,864
Ozempic Semaglutide Brand 32 $37,255
Mounjaro Tirzepatide Brand 19 $16,937
Eliquis Apixaban Brand 12 $13,405
Trelegy Ellipta Fluticasone/Umeclidin/Vilanter Brand 11 $6,929
Incruse Ellipta Umeclidinium Bromide Brand 11 $3,832
Levothyroxine Sodium Generic 198 $1,837
Propranolol Hcl Er Propranolol Hcl Brand 20 $1,675
Estradiol Generic 29 $1,547
Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen Brand 51 $1,463

The 10 drugs with the highest cost, of 67 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 229,976 Part D prescribers listed as Nurse Practitioner; they describe a distribution and say nothing about conduct.

Records

8 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record